AAPL336.13-0.87 (-0.26%) ▼|ABBV263.96-0.06 (-0.02%) ▼|ABT102.61+0.38 (+0.37%) ▲|ACN181.29-9.00 (-4.73%) ▼|ADBE248.92-3.75 (-1.48%) ▼|AMAT444.57+27.17 (+6.51%) ▲|AMD559.82+14.73 (+2.70%) ▲|AMGN385.65+5.87 (+1.55%) ▲|AMT173.98-1.60 (-0.91%) ▼|AMZN253.71+2.52 (+1.00%) ▲|AVGO357.61+10.31 (+2.97%) ▲|AXP311.56+0.39 (+0.13%) ▲|BA198.20+1.20 (+0.61%) ▲|BAC57.73-0.45 (-0.77%) ▼|BKNG167.90-2.62 (-1.54%) ▼|BLK1,069.78+15.82 (+1.50%) ▲|BMY63.06+0.22 (+0.35%) ▲|BNY153.79+0.77 (+0.50%) ▲|BRK-B509.77+0.57 (+0.11%) ▲|C131.77-0.93 (-0.70%) ▼|CAT808.99+10.42 (+1.30%) ▲|CL87.47-0.26 (-0.30%) ▼|CMCSA22.74-0.17 (-0.74%) ▼|COF202.43+0.39 (+0.19%) ▲|COP131.83-1.36 (-1.02%) ▼|COST895.31+1.38 (+0.15%) ▲|CRM237.92-4.93 (-2.03%) ▼|CSCO109.51-0.73 (-0.66%) ▼|CVS88.84-1.43 (-1.58%) ▼|CVX209.51-2.06 (-0.97%) ▼|DE683.99-1.64 (-0.24%) ▼|DHR211.81-0.69 (-0.32%) ▼|DIS102.67-2.68 (-2.54%) ▼|DUK117.53-1.01 (-0.85%) ▼|EMR149.92+2.52 (+1.71%) ▲|FDX303.65-2.23 (-0.73%) ▼|GD353.05-2.90 (-0.81%) ▼|GE314.27+0.80 (+0.26%) ▲|GEV940.33+15.40 (+1.67%) ▲|GILD150.11-0.78 (-0.52%) ▼|GM82.20-4.42 (-5.10%) ▼|GOOG344.41+0.73 (+0.21%) ▲|GOOGL349.54+2.21 (+0.64%) ▲|GS942.00-9.47 (-1.00%) ▼|HD299.98-2.53 (-0.84%) ▼|HON206.46-0.03 (-0.01%) ▼|IBM229.55-8.20 (-3.45%) ▼|INTC108.60-0.20 (-0.18%) ▼|INTU303.19-9.94 (-3.17%) ▼|ISRG393.33+9.79 (+2.55%) ▲|JNJ269.99-0.23 (-0.09%) ▼|JPM349.67+0.36 (+0.10%) ▲|KO88.25+0.19 (+0.22%) ▲|LIN460.40+1.92 (+0.42%) ▲|LLY1,152.93+0.49 (+0.04%) ▲|LMT533.38-4.71 (-0.88%) ▼|LOW192.49-1.70 (-0.88%) ▼|LRCX288.11+18.80 (+6.98%) ▲|MA565.24-0.49 (-0.09%) ▼|MCD248.24-0.24 (-0.10%) ▼|MDLZ60.85-1.19 (-1.92%) ▼|MDT92.13-0.64 (-0.69%) ▼|META665.75-16.56 (-2.43%) ▼|MMM165.89+1.18 (+0.72%) ▲|MO69.52-0.18 (-0.26%) ▼|MRK146.87-0.28 (-0.19%) ▼|MS202.58-0.94 (-0.46%) ▼|MSFT493.78-3.97 (-0.80%) ▼|MU1,015.80+38.30 (+3.92%) ▲|NEE80.47-0.81 (-1.00%) ▼|NFLX71.79-3.52 (-4.67%) ▼|NKE35.51-0.85 (-2.34%) ▼|NOW135.47-3.00 (-2.17%) ▼|NVDA222.27+2.93 (+1.34%) ▲|ORCL147.61-2.98 (-1.98%) ▼|PEP129.75-3.91 (-2.93%) ▼|PFE27.66+0.02 (+0.07%) ▲|PG146.39-1.16 (-0.79%) ▼|PLTR177.64+1.40 (+0.79%) ▲|PM188.62-1.86 (-0.98%) ▼|QCOM177.72-10.99 (-5.82%) ▼|RTX194.00+0.46 (+0.24%) ▲|SBUX95.83-0.84 (-0.87%) ▼|SCHW105.25+0.62 (+0.59%) ▲|SO85.52-1.24 (-1.43%) ▼|SPG205.32+0.85 (+0.42%) ▲|T25.40+0.01 (+0.04%) ▲|TMO651.45-6.87 (-1.04%) ▼|TMUS168.18+1.73 (+1.04%) ▲|TSLA364.27-1.93 (-0.53%) ▼|TXN266.64+8.50 (+3.29%) ▲|UBER70.50-0.37 (-0.52%) ▼|UNH376.90+1.69 (+0.45%) ▲|UNP279.37-3.11 (-1.10%) ▼|UPS99.06-1.11 (-1.11%) ▼|USB60.06-0.19 (-0.32%) ▼|V368.29-1.64 (-0.44%) ▼|VZ48.09-0.24 (-0.50%) ▼|WFC86.12-0.77 (-0.89%) ▼|WMT106.73-0.06 (-0.06%) ▼|XOM163.54+0.27 (+0.17%) ▲|AAPL336.13-0.87 (-0.26%) ▼|ABBV263.96-0.06 (-0.02%) ▼|ABT102.61+0.38 (+0.37%) ▲|ACN181.29-9.00 (-4.73%) ▼|ADBE248.92-3.75 (-1.48%) ▼|AMAT444.57+27.17 (+6.51%) ▲|AMD559.82+14.73 (+2.70%) ▲|AMGN385.65+5.87 (+1.55%) ▲|AMT173.98-1.60 (-0.91%) ▼|AMZN253.71+2.52 (+1.00%) ▲|AVGO357.61+10.31 (+2.97%) ▲|AXP311.56+0.39 (+0.13%) ▲|BA198.20+1.20 (+0.61%) ▲|BAC57.73-0.45 (-0.77%) ▼|BKNG167.90-2.62 (-1.54%) ▼|BLK1,069.78+15.82 (+1.50%) ▲|BMY63.06+0.22 (+0.35%) ▲|BNY153.79+0.77 (+0.50%) ▲|BRK-B509.77+0.57 (+0.11%) ▲|C131.77-0.93 (-0.70%) ▼|CAT808.99+10.42 (+1.30%) ▲|CL87.47-0.26 (-0.30%) ▼|CMCSA22.74-0.17 (-0.74%) ▼|COF202.43+0.39 (+0.19%) ▲|COP131.83-1.36 (-1.02%) ▼|COST895.31+1.38 (+0.15%) ▲|CRM237.92-4.93 (-2.03%) ▼|CSCO109.51-0.73 (-0.66%) ▼|CVS88.84-1.43 (-1.58%) ▼|CVX209.51-2.06 (-0.97%) ▼|DE683.99-1.64 (-0.24%) ▼|DHR211.81-0.69 (-0.32%) ▼|DIS102.67-2.68 (-2.54%) ▼|DUK117.53-1.01 (-0.85%) ▼|EMR149.92+2.52 (+1.71%) ▲|FDX303.65-2.23 (-0.73%) ▼|GD353.05-2.90 (-0.81%) ▼|GE314.27+0.80 (+0.26%) ▲|GEV940.33+15.40 (+1.67%) ▲|GILD150.11-0.78 (-0.52%) ▼|GM82.20-4.42 (-5.10%) ▼|GOOG344.41+0.73 (+0.21%) ▲|GOOGL349.54+2.21 (+0.64%) ▲|GS942.00-9.47 (-1.00%) ▼|HD299.98-2.53 (-0.84%) ▼|HON206.46-0.03 (-0.01%) ▼|IBM229.55-8.20 (-3.45%) ▼|INTC108.60-0.20 (-0.18%) ▼|INTU303.19-9.94 (-3.17%) ▼|ISRG393.33+9.79 (+2.55%) ▲|JNJ269.99-0.23 (-0.09%) ▼|JPM349.67+0.36 (+0.10%) ▲|KO88.25+0.19 (+0.22%) ▲|LIN460.40+1.92 (+0.42%) ▲|LLY1,152.93+0.49 (+0.04%) ▲|LMT533.38-4.71 (-0.88%) ▼|LOW192.49-1.70 (-0.88%) ▼|LRCX288.11+18.80 (+6.98%) ▲|MA565.24-0.49 (-0.09%) ▼|MCD248.24-0.24 (-0.10%) ▼|MDLZ60.85-1.19 (-1.92%) ▼|MDT92.13-0.64 (-0.69%) ▼|META665.75-16.56 (-2.43%) ▼|MMM165.89+1.18 (+0.72%) ▲|MO69.52-0.18 (-0.26%) ▼|MRK146.87-0.28 (-0.19%) ▼|MS202.58-0.94 (-0.46%) ▼|MSFT493.78-3.97 (-0.80%) ▼|MU1,015.80+38.30 (+3.92%) ▲|NEE80.47-0.81 (-1.00%) ▼|NFLX71.79-3.52 (-4.67%) ▼|NKE35.51-0.85 (-2.34%) ▼|NOW135.47-3.00 (-2.17%) ▼|NVDA222.27+2.93 (+1.34%) ▲|ORCL147.61-2.98 (-1.98%) ▼|PEP129.75-3.91 (-2.93%) ▼|PFE27.66+0.02 (+0.07%) ▲|PG146.39-1.16 (-0.79%) ▼|PLTR177.64+1.40 (+0.79%) ▲|PM188.62-1.86 (-0.98%) ▼|QCOM177.72-10.99 (-5.82%) ▼|RTX194.00+0.46 (+0.24%) ▲|SBUX95.83-0.84 (-0.87%) ▼|SCHW105.25+0.62 (+0.59%) ▲|SO85.52-1.24 (-1.43%) ▼|SPG205.32+0.85 (+0.42%) ▲|T25.40+0.01 (+0.04%) ▲|TMO651.45-6.87 (-1.04%) ▼|TMUS168.18+1.73 (+1.04%) ▲|TSLA364.27-1.93 (-0.53%) ▼|TXN266.64+8.50 (+3.29%) ▲|UBER70.50-0.37 (-0.52%) ▼|UNH376.90+1.69 (+0.45%) ▲|UNP279.37-3.11 (-1.10%) ▼|UPS99.06-1.11 (-1.11%) ▼|USB60.06-0.19 (-0.32%) ▼|V368.29-1.64 (-0.44%) ▼|VZ48.09-0.24 (-0.50%) ▼|WFC86.12-0.77 (-0.89%) ▼|WMT106.73-0.06 (-0.06%) ▼|XOM163.54+0.27 (+0.17%) ▲|
18.5 C
New York
Sunday, September 20, 2026

Tag: data

Ericsson and Google Cloud team up to deliver carrier-grade 5G core as-a-service built with AI at the foundation

Ericsson On-Demand delivers a significant shift in how core network services are deployed, managed and scaledProvisions core services in minutes, allowing Communication Service Providers...

Medical Second Opinion Market to Hit USD 19.03 Billion by 2029, Driven by Cancer and Chronic Care | Valuates Reports

BANGALORE, India, June 12, 2025 /PRNewswire/ -- Medical Second Opinion Market is Segmented by Type (Hospitals, Medical Second Opinion Providing Companies, Health Insurance Companies),...

Greater Than and Smart Eye Deepen Collaboration with Predictive Risk Scoring in Upgraded Driver Support System

Greater Than's AI-generated risk intelligence now integrated in Smart Eye's new version AIS system Predicts crashes in advance, improving risk management for fleet and transport...

Levicept to Present Further Analysis from Phase II Trial of Novel Neurotrophin-3 Inhibitor, LEVI-04, at EULAR

SANDWICH, United Kingdom, June 12, 2025 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis, is to present new data from its large-scale Phase II trial of LEVI-04 at EULAR, the European Congress of Rheumatology in Barcelona, Spain.

MemorialCare Long Beach Medical Center Recognized by Newsweek as One of America’s Best Hospitals in Cancer, Neurology, Orthopedics

LONG BEACH, Calif., June 12, 2025 /PRNewswire/ -- MemorialCare Long Beach Medical Center was named in Newsweek's 2025 America's Best Hospitals rankings in three...

MEXC Unveils $100 Million Guardian Fund to Safeguard Users Against Security Threats

VICTORIA, Seychelles, June 12, 2025 (GLOBE NEWSWIRE) -- MEXC, a leading global cryptocurrency exchange, has unveiled a groundbreaking $100 million Guardian Fund to enhance user safety and trust across its platform. This fund is designed to provide a strong safeguard for users facing severe security threats, such as large-scale exploits, targeted attacks, or unforeseen system vulnerabilities. In a move toward greater accountability, MEXC has made the fund fully transparent by disclosing wallet addresses publicly—setting a new industry standard for proactive risk management and user protection.

Liplyn IG Launches New International Platform for Business Information and News

Liplyn Information Group (Liplyn IG) is launching an international data and news platform focused on the SaaS, tech, finance, consulting, government, and SME sectors. AMSTERDAM,...

Enterome raises $19 million to fund clinical development of its OncoMimics™ immunotherapy to treat Follicular Lymphoma

Paris, France – June 12, 2025

Enterome SA
, a clinical-stage company developing first-in-class OncoMimics™ immunotherapies to treat cancer, has raised $19 million in a new private financing to advance its lead clinical program EO2463 OncoMimics™ immunotherapy to treat indolent non-Hodgkin lymphoma (iNHL). The new funds will be used to expand and finalize the ongoing Phase 1/2 SIDNEY clinical trial of EO2463 and prepare the candidate for a registrational trial.

GCL SI Joins TianGong Initiative as the First Solar PV Company, Pioneering Carbon Transparency in Supply Chains

SHANGHAI, June 12, 2025 /PRNewswire/ -- On the opening day of the 2025 SNEC PV Power Expo, GCL System Integration Technology Co., Ltd. ("GCL SI")...

Raytron Unveils an AI Thermal Imaging System for 24/7 Early Wildfire Prevention

YANTAI, China, June 12, 2025 /PRNewswire/ -- As early summer heatwaves sweep across the Northern Hemisphere, wildfire risk is rising sharply. Traditional manual patrols, hampered...

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia...

Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy.

NIRA Dynamics Strengthens Automotive Safety Through Strategic Partnership with BANF Intelligent Tire System

Strategic Partnership Enhances Safety and Efficiency in Trucking SAN FRANCISCO, June 12, 2025 /PRNewswire/ -- Swedish automotive software leader NIRA Dynamics AB is taking vehicle safety...

Real-world prospective data confirms improved risk stratification in multiple myeloma using SKY92 gene expression profiling

According to clinical guidelines, high-risk myeloma patients should receive intensified treatment regimens. However, heterogeneity in clinical markers and staging systems lead to various interpretations of...

Significant efficacy benefit of IMBRUVICA® (ibrutinib) plus venetoclax versus acalabrutinib plus venetoclax in frontline treatment of patients with chronic lymphocytic leukaemia suggested by indirect...

Cross-study findings indicate significant clinical benefit of frontline fixed-duration ibrutinib plus venetoclax with improved likelihood of undetectable minimal residual disease and progression-free survival versus acalabrutinib plus venetoclax1

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsData